Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity

TF Tedder, A Baras, Y Xiu - Springer seminars in immunopathology, 2006 - Springer
Immunotherapy using Rituximab, an unconjugated CD20 monoclonal antibody, has proven
effective for treating non-Hodgkin's lymphoma and autoimmune disease. CD19 antibody …
被引用次数：80 相关文章

Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity.

T Tedder, A Baras, Y Xiu - Springer Seminars in …, 2006 - search.ebscohost.com
Immunotherapy using Rituximab, an unconjugated CD20 monoclonal antibody, has proven
effective for treating non-Hodgkin's lymphoma and autoimmune disease. CD19 antibody …

Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity.

TF Tedder, A Baras, Y Xiu - Springer Seminars in Immunopathology, 2006 - europepmc.org
Immunotherapy using Rituximab, an unconjugated CD20 monoclonal antibody, has proven
effective for treating non-Hodgkin's lymphoma and autoimmune disease. CD19 antibody …

Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity

TF Tedder, A Baras, Y Xiu - Springer seminars in …, 2006 - pubmed.ncbi.nlm.nih.gov
Immunotherapy using Rituximab, an unconjugated CD20 monoclonal antibody, has proven
effective for treating non-Hodgkin's lymphoma and autoimmune disease. CD19 antibody …

Fc [gamma] receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity

TFTABY Xiu - Seminars in Immunopathology, 2006 - search.proquest.com
Immunotherapy using Rituximab, an unconjugated CD20 monoclonal antibody, has proven
effective for treating non-Hodgkin's lymphoma and autoimmune disease. CD19 antibody …

[引用][C] Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity

TF TEDDER, A BARAS… - Springer seminars in …, 2006 - pascal-francis.inist.fr
Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody
immunotherapies for B lymphocyte malignancies and autoimmunity CNRS Inist Pascal-Francis …

[引用][C] Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity

TF Tedder, A Baras, Y Xiu - Springer Seminars in Immunopathology, 2006 - cir.nii.ac.jp
Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody
immunotherapies for B lymphocyte malignancies and autoimmunity | CiNii Research CiNii 国立 …

Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity

TF Tedder, A Baras, Y Xiu - Seminars in Immunopathology, 2006 - infona.pl
Immunotherapy using Rituximab, an unconjugated CD20 monoclonal antibody, has proven
effective for treating non-Hodgkin's lymphoma and autoimmune disease. CD19 antibody …

Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity.

T Tedder, A Baras, Y Xiu - Springer Seminars in …, 2006 - search.ebscohost.com
Immunotherapy using Rituximab, an unconjugated CD20 monoclonal antibody, has proven
effective for treating non-Hodgkin's lymphoma and autoimmune disease. CD19 antibody …

[引用][C] Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity

TF Tedder, A Baras, Y Xiu - Springer Seminars in Immunopathology, 2006 - Springer